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Abstract: C–H functionalization is a chemically challenging but highly desirable transformation.
2-oxoglutarate-dependent oxygenases (2OGXs) are remarkably versatile biocatalysts for the activation
of C–H bonds. In nature, they have been shown to accept both small and large molecules carrying out
a plethora of reactions, including hydroxylations, demethylations, ring formations, rearrangements,
desaturations, and halogenations, making them promising candidates for industrial manufacture.
In this review, we describe the current status of 2OGX use in biocatalytic applications concentrating on
2OGX-catalyzed oxyfunctionalization of amino acids and synthesis of antibiotics. Looking forward,
continued bioinformatic sourcing will help identify additional, practical useful members of this
intriguing enzyme family, while enzyme engineering will pave the way to enhance 2OGX reactivity
for non-native substrates.
Keywords: 2-oxoglutarate-dependent oxygenases; industrial biocatalysis; hydroxylation; alpha-
ketoglutarate; amino acid modification; antibiotic synthesis
1. Introduction
Alkanes are important, easily obtainable building blocks for the chemical industry. They stem
from resources, such as gas and crude oil, but are also found in algae, bacteria, and plants and serve as
precursors for a wide range of agrochemicals and pharmaceuticals. However, the activation of alkanes
remains challenging in an industrial context due to the fact that carbon–hydrogen bonds are relatively
inert. Additionally, when employing substrates with multiple C–H bonds, obtaining satisfactory
chemo-, regio- and stereoselectivity remains problematic, while, at the same time, the oxidation state
of the final product can be difficult to control using conventional chemical catalysis [1].
Nature, in contrast, has perfected oxidation reactions, which are an integral part of the biosynthesis
of a diverse set of compounds, especially of secondary metabolites [2,3]. Nature’s repertoire of
oxidative biocatalysts can be mechanistically classified into two categories: dehydrogenation and
oxyfunctionalization catalysts [4]. Dehydrogenation catalysts abstract a hydrogen atom via an acceptor
molecule, such as a nicotinamide or flavin cofactor, but do not involve an active oxygen intermediate.
Oxyfunctionalization catalysts, on the other hand, reductively activate molecular oxygen or rely on
hydrogen peroxide for subsequent electrophilic substitution into the starting material. Synthetically,
oxyfunctionalization catalysts are more intriguing, as they can introduce new functional groups by
catalyzing the selective insertion of oxygen into C–H, C–C, and C=C bonds [4]. Harnessing the power of
precisely placed cofactors in the enzyme active site, C–H activating biocatalysts derivatize their substrates
regio- and stereospecifically at ambient temperature and pressure in aqueous solutions, thus eliminating
the challenges typically associated with chemical approaches.
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Today, biocatalytic C–H functionalization is already of substantial industrial importance for
chemical production processes ranging from the milligram production of drug metabolites [5–7] to the
biosynthetic manufacture of complex biomolecules in microorganisms [8–10]. In these biooxidation
applications, the most prominently used class of enzymes are the P450 monooxygenases (P450s). Due to
their ability to perform challenging regioselective and stereoselective activations of remote, unactivated
C–H, P450s have a long history of use in the pharmaceutical industry [7,11], a prominent example
being the use of fungal P450s for the production of steroids [12]. In addition, P450s are exploited for
the late-stage functionalization of added-value molecules [13,14] and in this context, an engineered
P450 enzyme has been recently employed in the total synthesis of nigelladine A, a norditerpenoid [15].
Thanks to significant advances in (semi-) rational protein engineering and directed evolution (2018
Nobel Prize in Chemistry), P450 variants performing new-to-nature C–H transformations, such as C–N
and C–C bond-forming processes, have been developed in the last years [16]. However, despite the
impressive successes in P450 engineering the preparative use of P450 enzymes is still limited to selected
examples because enzyme performance can be affected by inefficient electron transfer, uncoupling,
and low stability and activity [17,18].
Another heme-dependent enzyme family that has been associated with great potential for C–H
activation are the so-called ‘unspecific peroxygenases’ (UPOs), which use H2O2 instead of O2 as the
oxidant to drive numerous oxygenation reactions on a broad range of substrates without the need for
an electron delivery system [19]. These enzymes have been described to carry out reactions such as
alkane hydroxylations, aromatic hydroxylations, and epoxidations, as well as catalyzing oxidative
decarboxylations and the Achmatowicz reaction [20].
Besides the well-studied heme-dependent oxygenases, non-heme Fe(II)-dependent oxygenases,
in particular 2-oxoglutarate-dependent oxygenases (2OGXs), are an interesting alternative to carry out
desirable C–H activation chemistry [2,21]. 2OGXs constitute a diverse protein superfamily with members
from bacteria, fungi, plants, and vertebrates. Their biological function includes collagen biosynthesis,
plant and animal development, transcriptional regulation, nucleic acid modification/repair, fatty acid
metabolism, and secondary metabolite biosynthesis [22]. In plants and animals, 2OGXs catalyze reactions
during the biosynthesis of most of the major classes of secondary metabolites, including peptides, alkaloids,
terpenoids, carbohydrates, and mixed-origin molecules [23]. In microbes, 2OGXs also have additional roles
in sulfur and phosphate metabolism [2]. Catalyzed reactions cover a wide range, including hydroxylation,
dealkylation, desaturation, epoxidation, epimerization, cyclization, and halogenations [2,24] (Figure 1).
Industrially, this class of enzymes has been used mainly for the derivatization of amino acids and in
the biosynthesis of antibiotics, while other biotransformation processes have been less explored to date.
However, due to their chemical versatility, the biocatalytic use of 2OGX enzymes is continuously explored
in industry [25] and academia [21,26,27] and is considered to have high potential for sustainable, robust,
and scalable chemical synthesis [28].
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Figure 1. Examples of 2-oxoglutarate-dependent oxygenase-catalyzed reactions by representative 
members of this enzyme family. A) Hydroxylation of proline by L-proline hydroxylase AlP4H to form 
trans-4-hydroxy-L-proline [29]; B) Halogenation of 12-epi-Fischerindole U by WelO5 to yield 12-epi-
Fischerindole G [30]; C) Epoxidation of 4’-methoxyldehydroxy cyclopeptin by AsqJ to form 4’-
methoxylcyclopenin [31,32]; D) Oxidation of a tryptophan derivative by dioxygenase for auxinoxidation 
(DAO) to form the plant auxin indole-3-acetic acid [33–35]; E) O-demethylation of thebaine in 
morphinan alkaloid biosynthesis by codeine O-demethylase (CODM) [36]; F) Epimerization reaction in 
the carbapenem core structure maturation as catalyzed by CarC [37,38]; G) Ring expansion reaction of 
the penicillin N amide thiazolidine ring catalyzed by deacetoxycephalosporin C synthase (DAOCS) [39]; 
H, I) Ring formation and desaturation reaction in the biosynthesis of clavulanic acid catalyzed by 
trifunctional 2-oxoglutarate-dependent clavaminate synthase (CAS) [40]; J) Formation of an 
endoperoxide by FtmOx1 in verruculogen biosynthesis [41,42]. 
Structurally, 2OGX enzymes share distinctive features. Crystallographic studies show that the 
enzymes contain a double-stranded -helix core fold (DSBH, also known as a jelly roll, cupin, or jumonji 
C fold) composed of eight antiparallel -strands forming a -sandwich structure, which supports two 
His residues and (with exception of the halogenases) a carboxylate Glu or Asp residue [43]. This motif, 
also called the 2-His-1-carboxylate facial triad, is responsible for binding the Fe(II) center, whereas the 
other face of the metal coordinates three water molecules [44]. Aik et al. proposed that beyond housing 
the active site, the -strands also assist in providing selectivity for binding the primary substrates [45]. 
In the consensus view of the 2OGX reaction mechanism for hydroxylation activity (Figure 2), the most 
well-studied reactivity of 2OGX enzymes, two water molecules are displaced upon 2-oxoglutarate 
(2OG) chelation. 2OG binds to the Fe center in a bidentate configuration, in which the keto group is 
oriented opposite the Asp/Glu and its carboxylate opposite one of the His residues [46]. The binding of 
the primary substrate proximal to the metal center leads to the displacement of the remaining water 
molecule triggering the binding of dioxygen. In this way, the formation of the Fe(III)-superoxo species 
takes place, which initiates oxidative decarboxylation of 2OG to form succinate, CO2, and an Fe(IV) oxo 
Figure 1. a ples 2-oxogl tar t - oxygenase-catalyze reactions by repres nta ive
members of this enzyme family. (A) Hydroxylation f proline by L-proline h droxylase AlP4H
to form trans-4-hydroxy-L-proline [29]; (B) Hal genation of 12-epi-Fischerindole U by WelO5 to
yield 12-epi-Fischerindole G [30]; (C) Epoxidation of 4′-methoxyldehydroxy cyclopeptin by AsqJ
to form 4′-methoxylcyclopenin [31,32]; (D) Oxidation of a tryptophan derivative by dioxygenase for
auxinoxidation (DAO) to form the plant auxin indole-3-acetic acid [33–35]; (E) O-demethylation of
thebaine in morphinan alkaloid biosynthesis by codeine O-demethylase (CODM) [36]; (F) Epimerization
reaction in the carbapenem core structure maturation as catalyzed by CarC [37,38]; (G) Ring expansion
reaction of the penicillin N amide thiazolidine ring catalyzed by deacetoxycephalosporin C synthase
(DAOCS) [39]; (H,I) Ring formation and desaturation reaction in the biosynthesis of clavulanic acid
catalyzed by trifunctional 2-oxoglutarate-dependent clavaminate synthase (CAS) [40]; (J) Formation of
an endoperoxide by FtmOx1 in verruculogen biosynthesis [41,42].
Structurally, 2OGX enzymes share distinctive features. Crystallographic studies show that the
enzymes contain a double-strandedβ-helix core fold (DSBH, also known as a jelly roll, cupin, or jumonji
C fold) composed of eight antiparallel β-strands forming a β-sandwich structure, which supports two
His residues and (with exception of the halogenases) a carboxylate Glu or Asp residue [43]. This motif,
also called the 2-His-1-carboxylate facial triad, is responsible for binding the Fe(II) center, whereas the
other face of the metal coordinates three water molecules [44]. Aik et al. proposed that beyond housing
the active site, the β-strands also assist in providing selectivity for binding the primary substrates [45].
In the consensus view of the 2OGX reaction mechanism for hydroxylation activity (Figure 2), the most
well-studied reactivity of 2OGX enzymes, two water molecules are displaced upon 2-oxoglutarate
(2OG) chelation. 2OG binds to the Fe center in a bidentate configuration, in which the keto group is
oriented opposite the Asp/Glu and its carboxylate opposite one of the His residues [46]. The binding
of the primary substrate proximal to the metal center leads to the displacement of the remaining water
molecule triggering the binding of dioxygen. In this way, the formation of the Fe(III)-superoxo species
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takes place, which initiates oxidative decarboxylation of 2OG to form succinate, CO2, and an Fe(IV)
oxo species, also known as the ferryl intermediate. This ferryl intermediate abstracts a hydrogen from
an unactivated C(sp3)–H bond in the primary substrate yielding Fe(III)-OH and the substrate radical.
Hydroxyl radical rebound yields the hydroxylated product, which dissociates to complete the catalytic
cycle [24,47,48]. In cases where the carbon undergoing hydroxylation is bound to a heteroatom,
the initially formed product may spontaneously react further [24].
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Figure 2. Proposed consensus mechanism of 2-oxoglutarate-dependent oxygenase (2OGX)-catalyzed 
hydroxylation using the example of proline derivatization. Inset: A magnified view of the active site of 
MlP4H (Protein Data Bank (PDB) access code 4P7W) in complex with Co2+ (substituting for Fe(II) in 
crystallography), oxoglutarate (yellow), L-proline (yellow), and the coordinating His 106, Asp 108, and 
His 154 (cyan). Figure adapted from [2]. 
Notably, in 2OGX catalysis the electrons required for oxyfunctionalization of the unactivated 
C(sp3)–H bond stem from the cheap co-factor 2-oxoglutarate. In biocatalytic reactions, 2-oxoglutarate 
can be added from external sources; however, microbial metabolism may also provide this redox 
cofactor. The central carbon metabolism fuels 2OGX enzymes with 2-oxoglutarate and in turn 
assimilates and recycles the coproduct of the enzymatic reaction, namely succinate, through the 
tricarboxylic acid (TCA) cycle. Thus, metabolic engineering of microbial hosts to increase 2-oxoglutarate 
levels and force flux through the 2OGX biocatalyst is an attractive strategy to generate optimized cell 
factories. Using this approach, Theodosiou et al. and Smirnov et al. engineered the TCA cycle in 
Escherichia coli by deleting succinate-producing enzymes, thus optimizing 2OG flux for the production 
of trans-4-hydroxy-L-proline and trans-4-hydroxy-L-isoleucine, respectively [49,50]. Beyond their use as 
chassis strains for amino acid hydroxylation, these constructs also principally enable the selection of 
active 2OGX variants as the sole producers of succinate [49].  
In this review, we will highlight the biocatalytic utility of 2OGX enzymes by outlining the 
applications of 2OGXs in the hydroxylation of amino acid derivatives and of antibiotics (for a 
comprehensive overview of halogenation reactions please refer to [51,52]). Future implications of the 
rapidly increasing number of available genomes, as well as the increasing sophistication of enzyme 
engineering approaches, will also be discussed.  
Figure 2. Pro ose i of 2-oxoglutarate-dependent oxygenase (2OGX)-cat lyzed
hydroxylation using the example of proline derivatization. Inset: A magnified view of the active site
of MlP4H (Protein Dat Bank (PDB) access code 4P7W) in complex with Co2+ (substituting for Fe(II)
in crystallography), oxoglutarat (yellow), L-prolin (yellow), and the coordinating His 106, Asp 108,
and His 154 (cyan). Figure a apted from [2].
Notably, in 2 X catalysis the electrons required for oxyfunctionalization of the unactivated
C(sp3)–H bond stem fro the cheap co-factor 2-oxoglutarate. In biocatalytic reactions, 2-oxoglutarate
can be added from external sources; however, microbial metabolism may also provide this redox cofactor.
The central carbon metabolism fuels 2OGX enzymes with 2-oxoglutarate and in turn assimilates and
recycles the coproduct of the enzymatic reaction, na ely succinate, through the tricarboxylic acid
(TCA) cycle. Thus, metabolic engineering of microbial hosts to increase 2-oxoglutarate levels and force
flux through the 2OGX biocatalyst is an attractive strategy to generate optimized cell factories. Using this
approach, Theodosiou et al. and Smirnov et al. engineered the TCA cycle in Escherichia coli by deleting
succinate-producing enzymes, thus optimizing 2OG flux for the production of trans-4-hydroxy-L-proline
and trans-4-hydroxy-L-isoleucine, respectively [49,50]. Beyond their use as chassis strains for amino acid
hydroxylation, these constructs also principally enable the selection of active 2OGX variants as the sole
producers of succinate [49].
In this review, we will highlight the biocatalytic utility of 2OGX enzymes by outlining the applications
of 2OGXs in the hydroxylation of amino acid derivatives and of antibiotics (for a comprehensive overview
of halogenation reactions please refer to [51,52]). Future implications of the rapidly increasing number of
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available genomes, as well as the increasing sophistication of enzyme engineering approaches, will also
be discussed.
2. Biocatalytic Applications of 2-oxoglutarate-Dependent Oxygenases
Amino acid hydroxylation is the most common industrial application of 2-oxoglutarate-dependent
oxygenases to date (Figure 3). Several filed patents attest to the enzyme family’s potential for the
biocatalytic production of derivatized amino acids, which serve as building blocks for the chemical
industry [25,53–59]. Beyond amino acid hydroxylation, 2-oxoglutarate-dependent oxygenases are
explored for the synthesis of antibiotics, in the chemo-enzymatic total synthesis of complex natural
products, and as part of enzymatic cascade reactions for the production of valuable building blocks.
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Figure 3. Overview of selected amino acid hydroxylations by 2-oxoglutarate-dependent enzymes. The 
enzymes typically accept free-standing amino acids as a substrate. In cases where the substrate is part of 
a more complex molecule, the enzyme name is marked with an asterisk. 
2.1. Aliphatic amino acid oxygenases 
2.1.1. L-Isoleucine 4-hydroxylase or L-isoleucine dihydroxygenase (IDO) 
L-Isoleucine 4-hydroxylase from Bacillus thuringiensis converts L-isoleucine stereoselectively into 
(2S,3R,4S)-4-hydroxyisoleucine (4-HIL) [60], which was isolated for the first time from seeds of 
fenugreek (Trigonella foenum-graceum) [61]. The IDO-catalyzed conversion of L-isoleucine into 4-HIL 
(Figure 4) is patented by the Japanese company Ajinomoto Co. Inc. [58] and the Chinese company 
Henan Julong Bio-Engineering Co. Ltd. [62]. Studies on the properties of the hydroxylation product 
associate 4-HIL with anti-diabetic effects [63] and show that it is an effective drug for body weight 
control, glycemia, and insulinemia [64]. In Bacillus thuringiensis, 4-HIL is further converted into (2S,3R)-
2-amino-3-methyl-4-ketopentanoic acid, a vitamin B12 antimetabolite with antibiotic properties [65]. To 
boost 4-HIL production titers, an engineered E. coli strain lacking the isocitrate lyase and isocitrate 
dehydrogenase kinase/phosphatase was designed channeling endogenously produced co-substrate 2-
oxoglutarate toward the 2OGX [50]. Using this strain, 4-HIL yields were found to be 82%, employing 
100 mmol L-isoleucine as a substrate [50]. Recently, Zhang et al. enhanced the activity of IDO by 
introducing four mutations, which were identified by error-prone PCR [66]. Using this approach, the 
Figure 3. Overview of s lected amino acid hydroxylations by 2- xoglutarate-d pendent enzymes.
The enzymes typically acc pt free-standing amino acids as a substrate. In cas s w re the substrate is
part of a or complex mol cule, the enzyme name is marked with an asterisk.
2.1. Aliphatic Amino Acid Oxygenases
2.1.1. L-isoleucine 4-hydroxylase or L-isoleucine Dihydroxygenase (IDO)
L-isoleucine 4-hydroxylase from Bacillus thuringiensis converts L-isoleucine stereoselectively
into (2S,3R,4S)-4-hydroxyisoleucine (4-HIL) [60], which was isolated for the first time from seeds
of fenugreek (Trigonella foenum-graceum) [61]. The IDO-catalyzed conversion of L-isoleucine into
4-HIL (Figure 4) is patented by the Japanese company Ajinomoto Co. Inc. [58] and the Chinese
company Henan Julong Bio-Engineering Co. Ltd. [62]. Studies on the properties of the hydroxylation
product associate 4-HIL with anti-diabetic effects [63] and show that it is an effective drug for body
weight control, glycemia, and insulinemia [64]. In Bacillus thuringiensis, 4-HIL is further converted
into (2S,3R)-2-amino-3-methyl-4-ketopentanoic acid, a vitamin B12 antimetabolite with antibiotic
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properties [65]. To boost 4-HIL production titers, an engineered E. coli strain lacking the isocitrate
lyase and isocitrate dehydrogenase kinase/phosphatase was designed channeling endogenously
produced co-substrate 2-oxoglutarate toward the 2OGX [50]. Using this strain, 4-HIL yields were
found to be 82%, employing 100 mmol L-isoleucine as a substrate [50]. Recently, Zhang et al. enhanced
the activity of IDO by introducing four mutations, which were identified by error-prone PCR [66].
Using this approach, the kcat/Km value of IDO could be increased 1.5-fold to reach approximately
33 L/mmol/min, and the 4-HIL production doubled in a small-scale biocatalysis reaction [66].
In a study to investigate IDO’s substrate acceptance beyond L-isoleucine, recombinantly expressed
IDO was successfully tested for the hydroxylation of the aliphatic amino acids L-leucin, L-norleucine,
and L-norvaline and for the (S)-sulfoxidation of L-methionine and L-ethionine [67]. Exploiting this
substrate promiscuity, the Kourist group established a stereoselective three-enzyme cascade for
the synthesis of diasteromerically pure γ-oxyfunctionalized α-amino acids by combining IDO
with an N-acylamino acid racemase (NAAAR) and an L-selective aminoacylase from Geobacillus
thermoglucosidasius. In a one-pot strategy, 5 mM racemic N-acetylmethionine was quantitatively
converted into L-methionine-(S)-sulfoxide with a 97% yield and 95% diastereomeric excess [68].
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2.1.2. L-Isoleucine-4’-dioxygenase 
In contrast to the C4 selectivity of IDO, the 2-oxoglut ra -dep ndent oxyg nase HilA from Pantoea 
ananatis hydr xylates L-isoleucine on the C3 methyl group to produce 2-amino-3- 
(hydroxymeth l)pentanoic acid or 4’-hydroxyisoleucine [69,70]. In the native org nism a second 2OGX, 
named HilB, further processes 4’-hydroxyisoleucine into dihydroxylated 4,4’-dihydroxyisoleucine 
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Figure 4. Enzymatic L-isoleucine hydroxylation. Right: L-isoleucine dihydroxygenase (IDO)-catalyzed 
derivatization of L-isoleucine to form (2S,3R,4S)-4-hydroxyleucine; Left: Subsequent reaction of L-
isoleucine with HilA and HilB to generate the dehydroxylated 4,4’-dihydroxyisoleucine. 
2.1.3. L-Leucine 5-hydroxylase or L-leucine dioxygenase from cyanobacteria 
To date, three L-leucine dioxygenases from various cyanobacteria have been investigated. The first 
enzyme, LdoA, was isolated from Nostoc punctiforme PCC73102 [71]. The characterization of its substrate 
acceptance highlighted the capability of this enzyme to hydroxylate L-leucine into (2S,4S)-5-
hydroxyleucine and L-norleucine into (2S)-5-hydroxynorleucine and to carry out sulfoxidation of L-
methionine and L-ethionine [71]. Recently, oxygenase NpLDO from Nostoc piscinale possessing 72% 
sequence identity to LdoA [72] and AvLDO from Anabaena variabilis [73] were analyzed. While the 
studies highlighted that both enzymes exhibit a similar substrate spectrum to LdoA, e.g., hydroxylation 
of L-isoleucine into (2S,4S)-5-hydroxyleucine and sulfoxidation of L-methionine, AvLDO shows a 
differing enantiopreference and forms L-methionine-(R)-sulfoxide in contrast to the (S)-enantiomer 
formed with L-Isoleucine 4-hydroxylase (IDO). 
2.1.4. L-Leucine 5-hydroxylase from Streptomyces 
Manzacidins A–C, a family of bromopyrrole alkaloids with suspected biological activities, were 
first isolated from the Okinawan sponge Hymeniacidon sp. by Kobayashi et al. in 1991 [74,75]. 
Manzacidins possess a unique structure consisting of an ester-linked bromopyrrolecarboxylic acid and 
a 3,4,5,6-tetrahydropyrimidine ring in which one of the amino groups is attached to the C6 quaternary 
carbon center [75]. Several strategies for the total synthesis of manzacidin A and C were developed in 
the early years of the 21st century, generating mg amounts of the final product [75]. In contrast to the 
purely chemical approach, Renata and co-workers investigated a chemo-enzymatic route to produce 
manzacidin C, harnessing the 2-oxoglutarate-dependent leucine 5-hydroxylase GriE from Streptomyces 
sp. DSM40835 [76]. GriE has been implicated in the biosynthesis of the anti-tuberculosis molecules 
Figure 4. Enzymatic L-is le i . i t: L-isoleucine dihydroxygenase (IDO)-cat lyzed
derivatization of L-isoleucine to form (2S,3R,4S)-4-hydroxyleucine; Left: Subsequent reaction of
L-isoleucine with HilA and HilB to generate th dehydroxylated 4,4′-dihydroxyisoleucine.
2.1.2. L-isoleucine-4′-dioxygenase
In contrast to the C4 selectivity of IDO, the 2-oxoglutarate-dependent oxygenase HilA
from Pantoea ananatis hydroxylates L-isoleucine on the C3 methyl group to produce 2-amino-3-
(hydroxymethyl)pentanoic acid or 4′-hydroxyisoleucine [69,70]. In the native organism a second 2OGX,
named HilB, further processes 4′-hydroxyisoleucine into dihydroxylated 4,4′-dihydroxyisoleucine
(Figure 4). In another study, Smirnov et al. investigated the substrate scope of HilA and showed
promiscuous activity for the conversion of L-valine into L-4-hydroxyvaline [70].
2.1.3. L-leucine 5-hydroxylase or L-leucine Dioxygenase from Cyanobacteria
To date, three L-leucine dioxygenases from various cyanobacteria have been investigated.
The first enzyme, LdoA, was isolated from Nostoc punctiforme PCC73102 [71]. The characterization
of its substrate acceptance highlighted the capability of this enzyme to hydroxylate L-leucine
into (2S,4S)-5-hydroxyleucine and L-norleucine into (2S)-5-hydroxynorleucine and to carry out
sulfoxidation of L-methionine and L-ethionine [71]. Recently, oxygenase NpLDO from Nostoc piscinale
possessing 72% sequence identity to LdoA [72] and AvLDO from Anabaena variabilis [73] were analyzed.
While the studies highlighted that both enzymes exhibit a similar substrate spectrum to LdoA,
e.g., hydroxylation of L-isoleucine into (2S,4S)-5-hydroxyleucine and sulfoxidation of L-methionine,
AvLDO shows a differing enantiopreference and forms L-methionine-(R)-sulfoxide in contrast to the
(S)-enantiomer formed with L-isoleucine 4-hydroxylase (IDO).
2.1.4. L-leucine 5-hydroxylase from Streptomyces
Manzacidins A–C, a family of bromopyrrole alkaloids with suspected biological activities,
were first isolated from the Okinawan sponge Hymeniacidon sp. by Kobayashi et al. in 1991 [74,75].
Manzacidins possess a unique structure consisting of an ester-linked bromopyrrolecarboxylic acid
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and a 3,4,5,6-tetrahydropyrimidine ring in which one of the amino groups is attached to the C6
quaternary carbon center [75]. Several strategies for the total synthesis of manzacidin A and C were
developed in the early years of the 21st century, generating mg amounts of the final product [75].
In contrast to the purely chemical approach, Renata and co-workers investigated a chemo-enzymatic
route to produce manzacidin C, harnessing the 2-oxoglutarate-dependent leucine 5-hydroxylase
GriE from Streptomyces sp. DSM40835 [76]. GriE has been implicated in the biosynthesis of the
anti-tuberculosis molecules griselimycins found in Streptomyces sp. [77] by converting L-leucine into
(2S,4R)-5-hydroxyleucine [78]. Investigations of GriE’s substrate scope demonstrated the enzyme’s
ability to hydroxylate at least 13 amino acid derivatives with useful turnovers. While substitutions at
the γ position of the amino acid analogs were generally accepted, the enzyme proved to be sensitive
to substitution at the β position [76]. For the total chemo-enzymatic synthesis of manzacidin C
(Figure 5), photocatalytically produced azidoleucine (134 mg) was selectively δ-hydroxylated with
95% conversion using purified enzyme. Next, three additional chemical steps yielded the final product
manzacidin C with complete stereocontrol shortening the known chemical routes substantially [76].
In an alternative set-up, the same group highlighted the possibility of generating manzacidin C via the
gram scale hydroxylation of L-leucine by whole cell biocatalysis. The total synthesis consisting of nine
steps led to the desired product in 11% total yield from L-leucine [79].
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acetyl, and N-carbamyl-L-leucine, as well as N-succinyl-L-valine, N-succinyl-L-isoleucine and N-
succinyl-L-phenylalanine were accepted as substrates [84,85]. Furthermore, the enzyme was shown to 
have very low activity for the hydroxylation of N-succinyl-L-3,4-dimethoxyphenylalanine (NSDOPA) 
to yield N-succinyl-L-threo-3,4-dimethoxy-phenylserine (NSDOPS), a precursor of the psychoactive 
drug L-threo-3,4-dihydroxyphenylserine (Droxidopa) [86]. Using structure-based protein engineering, 
two mutations could be identified (G79A and F261R/W), which enhanced the activity for conversion of 
NSDOPA six-fold [86].  
Figure 5. Total chemo-enzymatic synthesis of manzacidin C and cavinafungin B. The key building
blocks (2S, 4S)-5-hydroxyleucine and (2S, 4R)-4-methylproline were repared enzymatically using the
2-oxoglutarate-dependent oxygenase GriE.
In elevated concentrations, GriE can convert L-leucine into the corresponding imine by double
oxidation at C5. The resulting imine can be reduced to (2S,4R)-4-methylproline [76], an important
building block for the synthesis of depsipeptide antibiotics or the antifungal agent cavinafungin B [80].
Cavinafungin B, an aldehyde lipopeptide isolated from Colispora cavincola in 2015 [81], is a close
analogue to cavinafungin A, which was recently shown to possess antiviral properties against the
Dengue virus and the Zika virus [82]. The total synthesis of cavinafungin B (37% final yield) was
carried out via a 10-step Fmoc-based solid-phase peptide synthesis (SPPS) using chemo-enzymatically
generated (2S,4R)-4-methylproline as a key building block (Figure 5) [80].
2.1.5. N-Succinyl L leucine 3-hydroxylase
The 2OGX SadA from Burkholdria ambifaria AMMD has a unique amino acid sequence possessing
no close homologue within the class of amino acid hydroxylases. SadA catalyzes the reaction of
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N-succinyl-L-leucine into N-succinyl-L-threo-β-hydroxyleucine with 99% diastereoselectivity [83].
No activity could be detected for the conversion of L-leucine or N-succinyl-D-leucine, but N-formyl,
N-acetyl, and N-carbamyl-L-leucine, as well as N-succinyl-L-valine, N-succinyl-L-isoleucine and
N-succinyl-L-phenylalanine were accepted as substrates [84,85]. Furthermore, the enzyme was shown
to have very low activity for the hydroxylation of N-succinyl-L-3,4-dimethoxyphenylalanine (NSDOPA)
to yield N-succinyl-L-threo-3,4-dimethoxy-phenylserine (NSDOPS), a precursor of the psychoactive
drug L-threo-3,4-dihydroxyphenylserine (Droxidopa) [86]. Using structure-based protein engineering,
two mutations could be identified (G79A and F261R/W), which enhanced the activity for conversion
of NSDOPA six-fold [86].
Notably, SadA was also found to have application in an enzymatic cascade reaction for the
production of β-hydroxy amino acids. In this study, SadA was coupled with the N-succinyl L-amino
acid desuccinylase (LasA) in a sequential mode [87]. First, 50 mM N-succinyl-L-leucine was converted
by SadA into N-succinyl L-threo- β-hydroxyleucine in 24 h (97 % conversion) before incubation with
LasA yielded L-threo- β-hydroxyleucine (93% conversion, >99% diastereomeric excess) [87].
2.2. Dioxygenase for Auxinoxidation and Fumitremorgin Oxygenases
Tryptophan or indole-derived natural products are common in nature, and the literature provides
evidence that 2-oxoglutarate-dependent enzymes are involved in their biosynthesis. In plants, for example,
the dioxygenase for auxinoxidation (DAO) from Arabidopsis hydroxylates the natural product auxin
indole-3-acetic acid into the inactive 2-oxoindole-3-acetic acid [33–35], while the microbial FtmOx1 from
Aspergillus fumigatus catalyzes the conversion of fumitremorgin B into the mycotoxin verruculogen. FtmOx1
operates by inserting an endoperoxide bond between two prenyl moieties [41,42]. This enzymatic activity
is dependent on a specific residue, Tyr 244, which has been identified by mechanistic and structural
studies [88,89]. However, despite their interesting activities, these enzymes have not yet featured in
biocatalytic applications.
2.3. L-proline Hydroxylases
In nature, hydroxyprolines are the building blocks of small molecules, such as actinomycin 1 or
etamycin, but also occur as part of proteins. A class of 2-oxoglutarate-dependent oxygenases named
proline hydroxylases (PHs) can catalyze the conversion of L-proline either into 3-hydroxy-L-proline or
4-hydroxy-L-proline [51]. The first described PH was isolated from Streptomyces griseoviridus P8648
(SgP4H) in 1994. It selectively epoxidizes 3,4-dehydro-L-proline, yielding trans-3,4-epoxy-L-proline [90].
Since then, a number of additional PHs have been discovered and characterized, and today, all four
monohydroxy-isomers of L-proline can be produced enzymatically (Table 1). However, it should be
noted that trans-3-hydroxy-L-proline is only formed as a side product by the enzymes HtyE and GloF,
two enzymes, which are known to preferentially produce trans-4-hydroxyproline [91].
Table 1. List of proline hydroxylases classified according to their substrate preference (not exhaustive).
Product Name Source Organism
cis-3-hydroxy-L-proline Cis-P3H1 (type I) Streptomyces sp. Th1 [92,93]
Cis-P3H2 (type II) Streptomyces sp. Th1 [94]
GetF Streptomyces sp. [95]
PiFa Frankia alni [95]
cis-4-hydroxy-L-proline SmP4H Sinorhizobium meliloti [96,97]
MlP4H Mesorhizobium loti [96]
SrPH Streptosporangium roseum [98] 1
CaPH Catenulispora acidiphila [98] 1
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Table 1. List of proline hydroxylases classified according to their substrate preference (not exhaustive).
Product Name Source Organism
trans-4-hydroxy-L-proline AlP4H Alteromonas mediterranea [29]
MiP4H Micromonospora sp. CNB394 [29]
ScP4H Sorangium cellulosum [29]
UbP4H Uncultured bacterium esnapd13 [99]
DaP4H Dactylosporangium sp. strain RH1 [100,101]
HtyE Aspergillus pachycristatus [91] 2
GloF Glarea lozoyensis [91,102,103] 2
P4HP Pseudomonas stutzeri [104]
P4HB Bordetella bronchiseptica [104]
trans-3-hydroxy-L-proline HtyE Aspergillus pachycristatus [91] 2
GloF Glarea lozoyensis [91,102,103] 2
1 mainly cis-4 hydroxyproline. 2 mainly trans-4 hydroxyproline.
The company Kyowa Hakko Kogyo has patented several PH-based processes. In an initial patent,
the company protects the use of a 2-oxoglutarate-dependent oxygenase, namely cis-P3H1, for the
production of cis-3-hydroxy-L-proline [55]. They describe the use of the purified enzyme to convert
L-proline (20 mM) into cis-3-hydroxy-L-proline (18mM) in 30 min. Additional patents of the same
company cover the production of cis-4-hydroxy-L-proline using SmP4H [56] and the manufacture of
trans-4-hydroxy-L-proline with DaP4H [54]. In the latter case, strain optimization took place, and by
expressing DaP4H with a tryptophan tandem promotor, the desired product trans-4-hydroxy-L-proline
could be obtained in titers of up to 41 g/L (87% yield) in 100 h [101]. Beyond Kyowa Hakko,
the Japanese company API Corp holds a patent for the production of cis-5-hydroxypipecolic acid using
a proline hydroxylase from Xenorhabdus sp. [53].
Other proline hydroxylases also accept the industrially important structural homolog pipecolic acid.
Klein et al. used Cis-P3H1, SmP4H, and DaP4H for the synthesis of hydroxypipecolic acid isomers [105].
To improve SmP4H’s regioselectivity in the conversion of pipecolic acid, Codexis Inc. optimized
the enzyme by protein engineering, yielding a variant capable of a more selective conversion of
L-pipecolic acid into cis-5-hydroxypipecolic acid [25,57]. Interestingly, the fungal enzymes GetF and PiFa
preferentially accept pipecolic acid, whereas L-proline is converted only to a very small extent. Using
site-directed mutagenesis, the group of Hüttel attempted to shift enzyme activity towards L-proline,
albeit with little success [95].
In some cases, the biocatalytic use of proline hydroxylases can be hampered by their low
temperature stability. In a recent study, Liu et al. addressed this problem for enzyme UbP4H by
loop grafting and site-directed mutagenesis improving Tm from 43 ◦C to 46 ◦C [99].
2.4. L-Hydroxyasparagine Oxygenases
Calcium-dependent antibiotics (CDAs) are structurally related acidic lipopeptide antibiotics,
which possess a decapeptide lactone or a lactam motif containing non-proteinogenic amino acids and
feature N-terminal fatty acid side chains [106]. The most prominent representative of this antibiotic
class is daptomycin [107]. L-3-hydroxy-asparagine is an important building block for the biosynthesis
of CDAs in Streptomyces coelicolor [106]. The hydroxylation of L-asparagine is catalyzed by asparagine
oxygenase (AsnO) [108]. By solving the crystal structure of AsnO with a resolution of 1.45 Å, Striecker
and coworkers demonstrated that only free L-asparagine can be converted by the enzyme, whereas
the late-stage functionalization of CDA or the acceptance of an asparagine bound to a peptidyl carrier
protein was excluded [109]. Using protein engineering, the group succeeded in switching substrate
acceptance to L-aspartic acid. Upon the introduction of only one mutation (D241N), the enzyme
produced L-3-hydroxy-aspartic acid exclusively, albeit with a loss of catalytic efficiency (the wildtype
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has a 300-time higher kcat) [110]. The preparative synthesis of L-3-hydroxy-aspartic acid was also
demonstrated on the scale of 18 mg with a purified protein [110].
2.5. L-Arginine Oxygenase
The tuberactinomycins (Tbms) are nonribosomal peptide antibiotics including viomycin
(tuberactinomycin B) and the capreomycins, which exhibit activity against Mycobacterium tuberculosis.
The compounds exhibit a range of biological activities that center on their ability to bind RNA and
disturb bacterial protein biosynthesis [111]. The gene cluster that directs viomycin biosynthesis
from Streptomyces vinaceus ATCC 11861 comprises the 2-OGX VioC [112]. VioC is involved
in the production of the building block (2S,3R)-capreomycidine by hydroxylation of L-arginine
into (2S,3S)-hydroxyarginine [113], which is then converted by the PLP-dependent VioD into
(2S,3R)-capreomycidine [114]. Apart from L-arginine, VioC can also hydroxylate L-homoarginine
and L-canavanine [115] and, interestingly, also accepts D-arginine, catalyzing an oxidative deamination
into the corresponding 2-oxo-5-guanidinopentanoate (2O5GP) [116].
In a biocatalytic context, VioC has been used together with an arginase and an ornithine
cyclodeaminase to convert L-arginine into trans-3-hydroxy-L-proline, which is difficult to selectively
produce using proline hydroxylases [117]. Despite successfully setting up the enzymatic cascade,
Hara et al. concluded that long reaction times (72 h) and low ornithine cyclodeaminase activity make
industrial applications unlikely at this time [117].
2.6. L-Lysine Hydroxylase
In 2015, two groups independently discovered a non-ribosomal tetrapeptide (JBIR-126 [118] or
tambromycin [119]) containing a characteristic indole substructure, an oxazoline moiety, and a novel
pyrrolidine-containing amino acid (named “tambroline”, which stands for two-amino-beta- homoproline)
coupled with a C-terminal α-methylserine residue.
The protected building block tambroline can be synthesized by selective C3 hydroxylation
of L-lysine, employing the 2-OXG lysine hydroxylase KDO1 from Catenulispora acidiphila (DSM
44928) [120,121] followed by an additional four chemical steps [122]. The biocatalytic transformation
was established on a 4 g scale (35 mM) using a crude cell lysate of KDO1 (>99% conversion) [122].
The chemo-enzymatic total synthesis of tambromycin consisted of 10 steps and led to the desired
product with an overall yield of 2.4%. By comparison, in a recently published purely chemical
synthesis consisting of 13 steps, tambromycin was obtained with an overall yield of 1.3% [123],
positively underscoring the potential of chemo-enzymatic setups.
Apart from KDO1, six additional lysine hydroxylases (K3H1, K3H2, K4H1, K4H2, K4H3, and K4H4)
are known for the regio- and stereoselective hydroxylation of the C-3 or C-4 position in L-lysine [124].
To explore their biocatalytic usefulness, Hara et al. conducted several multi-gram scale hydroxylation
reactions: Using K3H1 from Kineococcus radiotolerans (SRS30216) and K4H4 from Chryseobacterium gleum
(ATCC 35910), the desired products (2S,3S)-3-hydroxylysine (531 mM; 86.1 g/L; 88% molar conversion
in 52h) and (2S,4R)-4-hydroxylysine (265 m; 43 g/L, 88% molar conversion in 24h), respectively, could be
synthesized in batch-scale experiments [124]. All of these enzymes are mentioned in a patent by API
Corp. protecting the production of hydroxylysine [59].
2.7. L-Glutamate Hydroxylase
Two 2-oxoglutarate-dependent enzymes, namely KtzO and KtzP, are involved in the natural
synthesis of the antifungal and antimicrobial kutznerides [125]. In this specific case, the substrate
L-glutamate is bound to a peptidyl carrier to enable conversion to threo-L-hydroxyglutamic acid by
KtzO or erythro-L-hydroxyglutamic acid by KtzP [125]. Both enzymes cannot convert free-standing
L-glutamate.
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2.8. Clavaminate Synthase
Clavulanic acid is an effective β-lactamase inhibitor and therefore often used in combination with
β-lactam antibiotics to overcome antibiotic resistances [126]. The trifunctional 2-oxoglutarate-dependent
clavaminate synthase (CAS) from Streptomyces clavuligerus catalyzes three distinct steps in the compound’s
biosynthesis, namely hydroxylation of deoxyguanidino-proclavaminate, cyclization of proclavimic acid,
and desaturation of dihydroclavimic acid (Figure 6) [40]. In Streptomyces clavuligerus, two isoenzymes
CS1 and CS2 were identified and structurally and mechanistically characterized [127–130]. Interestingly,
fermentation optimization of Streptomyces clavuligerus is a field of ongoing study [131–133], and to date,
the production of clavulanic acid by fermentation has not yet substantially exceeded 1 g/L [131].  
 
 
Figure 6. Biosynthesis of clavulanic acid. The tri-functional oxygenase CAS sequentially carries out a 
hydroxylation, ring formation, and desaturation step. 
2.9. Deacetoxycephalosporin C synthase (DAOCS) and deacetylcephalosporin C synthase (DACS) 
Cephalosporins are a class of beta-lactam antibiotics originally derived from the fungus 
Acremonium [134]. The ring expansion of the penicillin N amide thiazolidine ring to form the 
dihydrothiazine caphem ring, a key step in the biosynthesis of cephalosporins, is catalyzed by the 2-
oxoglutarate-dependent eacetoxycephalosporin C synthase (DAOCS) before the second 2-oxoglutarate-
dependent deacetylcephalosporin C synthase (DACS) hydroxylates at C-3’ position to form 
deacetylcephalosporin C (Figure 7) [39]. In eukaryotic microorganisms, a single bifunctional enzyme 
called DAOCS/DACS catalyzes both reactions [135], whereas in prokaryotes two distinct enzymes are 
needed [136,137].  
 
Figure 7. Reactions catalyzed by DAOCS and DACS in the biosynthesis of cephalosporins. 
Industrially, penicillin G is a more abundantly available starting material than penicillin N, which 
is the natural substrate of DAOCS. However, wildtype DAOCS accepts penicillin G poorly, a fact that 
triggered a number of enzyme engineering studies to improve the activity of DAOCS for this non-
natural substrate [28,138–140]. Single mutations have already had a profound effect on DAOCS activity; 
for example, mutation N304K increases the kcat /Km value for the conversion of penicillin G from 18 M−1 
s−1 to 256 M−1 s−1 [141]. In a different study, error-prone PCR yielded a quadruple DAOCS mutant 
(C155Y/Y184H/V275I/C281Y) with a 40-fold improvement in kcat /Km [142], while further engineering 
generated a variant with a 118-fold improved kcat /Km value compared with the wildtype [143]. 
3. Conclusion 
Due to the explosion of available genome information, bioinformatic studies continuously identify 
additional members of the 2OGX superfamily in bacteria, metazoa, and plants [144–146]. This wealth of 
available enzyme sequences will lead to the characterization of additional, industrially promising 2OGX 
variants with desirable substrate spectra. Already today, 2-oxoglutarate-dependent oxygenases are 
employed for a variety of industrially and academically relevant transformations, ranging from the 
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activity; for example, mutation N304K increases the kcat/Km value for the conversion of penicillin G from
18 M−1 s−1 to 256 M−1 s−1 [141]. In a different study, error-prone PCR yielded a quadruple DAOCS mutant
(C155Y/Y184H/V275I/C281Y) with a 40-fold improvement in kcat/Km [142], while further engineering
generated a variant with a 118-fold improved kcat/Km value compared with the wildtype [143].
3. Conclusions
Due to the explosion of available genome information, bioinformatic studies continuously identify
additional members of the 2OGX superfamily in bacteria, metazoa, and plants [144–146]. This wealth
of available enzyme sequences will lead to the characterization of additional, industrially promising
2OGX variants with desirable substrate spectra. Already today, 2-oxoglutarate-dependent oxygenases
are employed for a variety of industrially and academically relevant transformations, ranging from
the production of amino acid derivatives to the chemo-enzymatic total synthesis of complex natural
products (vide supra). As attested by recent enzyme engineering studies on 2-oxoglutarate-dependent
oxygenases [25,99,140], the progress made in the field of protein design and evolution over the
last few decades [147,148] facilitates the development of robust and active C–H functionalization
biocatalysts [149]. As the integration of automation and the use of advanced computer algorithms
continue to facilitate enzyme engineering, the industrial implementation of 2OGX-driven processes
will be further accelerated.
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